deutraMed to Attend mRNA-Based Therapeutics Summit Europe

deutraMed to Attend mRNA-Based Therapeutics Summit Europe

January 24-26, 2023

Berlin, Germany

deutraMed Chief Scientist Dr. Pavel Gris will attend the mRNA-Based Therapeutics Summit Europe, to be held in Berlin, Germany in January 2023.

Dr. Gris, PhD, MRSC, C. Chem. and an Adjunct Professor in University of Waterloo’s Department of Chemistry, will join more than 250 leaders and scientists from academia and the pharmaceutical and biotech industries at the conference. Speakers and attendees will share updates to help advance mRNA-based vaccine and therapeutic strategies.

With the introduction of mRNA-based Covid-19 vaccines over the past few years, academics and industrial participants in this field are actively exploring the development and deployment of other mRNA-based therapies to combat diabetes, cancer, cardiovascular diseases, infectious diseases and other medical conditions.

Dr. Gris leads a team at deutraMed that has developed a proprietary method to stabilize mRNA using deuterium, based on the company’s Biomolecule Stabilization Technology platform. Initial study results demonstrate that the method can stabilize mRNA for 8+ months at refrigerator temperatures and 7+ days at room temperature. This would overcome significant cost and logistics challenges arising from the current need for ultra-cold storage and transportation of mRNA vaccines and other therapeutics.

To connect with Dr. Gris and other members of the deutraMed team, please call 1 (833) 338-8726 or send an email to

For more information about the conference, visit